Skip to main content
Gian Matteo Pica on Muck Rack

Gian Matteo Pica

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Gian Matteo

Contact Gian Matteo, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Allogeneic hematopoietic stem cell transplantation after azacitidine and venetoclax salvage in relapsed/refractory AML: a multicenter real-world study by the French AURAML group

|
By Gaspar Aspas Requena, Zofia Gross, Emmanuelle Tavernier, Pedro Chorão, Martin Carré, Adrien Contejean, Sylvain Lamure, Arthur Dony, Mauricette Michallet, Amine Belhabri, Maël Heiblig, Urbain Tauveron-Jalenques, Jérôme Cornillon, Clémence Santana, Natacha Mauz, Ugo Thevenet, Nadine Boullanger, Gian Matteo Pica
| Nature Verified
Abstract Fit relapsed/refractory (R/R) acute myeloid leukemia (AML) patients usually undergo intensive chemotherapy (IC)-based salvage to bridge them to allogeneic hematopoietic stem cell transplantation (HSCT), but their prognosis remains poor. Azacitidine and venetoclax (AZA/VEN) are increasingly used as salvage therapy in R/R AML with encouraging results, although data remain limited.
Open in Who Shared Issue with article?
See all 1 articles